iPS Cells & Regenerative Medicine– category –
-
K Pharma Advances Diverse Pipeline: Six iPSC-Based Drug Discovery Programs and Five Regenerative Medicine Projects in Progress
Kabutan.jp Japan Overview K Pharma's Q1 financial report reveals steady progress across its iPSC-based drug discovery and regenerative medicine divisions. The company is actively developing six pipelines in drug discovery and five pipeli... -
Japan’s PMDA Enhances Regulatory Framework for Regenerative Medicine Products Amidst Continuous Updates
独立行政法人 医薬品医療機器総合機構 (PMDA) Japan Overview Japan's Pharmaceuticals and Medical Devices Agency (PMDA) implemented several regulatory updates from May 8-15, 2026, pertaining to pharmaceuticals and regenerative medicine produ... -
Japan Approves First Regenerative Medicine Product for Meniscus Injury; University of Tokyo Uncovers T-cell Reprogramming Mechanism
国立研究開発法人日本医療研究開発機構 (AMED) Japan Overview Japan's AMED announced the approval of Fujifilm Toyama Chemical's "Saviskas Injection," the nation's first regenerative medicine product for meniscus injuries, on May 8, 2026. Si... -
Japan Approves Edostiladrin Gene Therapy for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer, Offering Bladder Preservation
Oncolo.jp Japan Overview Ferring Pharmaceuticals has received manufacturing and marketing approval in Japan for Edostiladrin (nadofaragene firadenovec), a gene therapy for BCG-unresponsive high-risk non-muscle invasive bladder cancer (NM... -
Japan Approves Pricing for World’s First iPSC-Derived Product, Amchepry, Signaling New Era for Regenerative Medicine
薬事日報 Japan Overview Japan's Central Social Insurance Medical Council has approved the official drug pricing for three new regenerative medicine products, including Sumitomo Pharma's iPSC-derived dopamine neural progenitor cells, Amch... -
Genprex Collaborators Report Positive Preclinical Data for Diabetes Gene Therapy at ASGCT 2026, Showing Alpha-to-Beta Cell Reprogramming
PR Newswire USA Overview Genprex's collaborators presented positive preclinical data at ASGCT 2026 for GPX-002, a gene therapy candidate for Type 2 Diabetes (T2D). The therapy, which delivers Pdx1/MafA genes to the pancreas via an AAV ve... -
Precision BioSciences Unveils Promising Preclinical Data for In Vivo Gene Editing Therapy in Duchenne Muscular Dystrophy
Morningstar USA Overview Precision BioSciences has presented encouraging preclinical data for PBGENE-DMD, an in vivo gene editing therapy targeting Duchenne Muscular Dystrophy, at the 2026 ASGCT Annual Meeting. Early intervention in youn...
